Potential linkage between dipeptidyl peptidase‐4 inhibitor use and the risk of pancreatitis/pancreatic cancer

Dipeptidyl peptidase (DPP)-4 inhibitors, a class of oral hypoglycemic agents, are widely used, especially in Asian populations, as they have been shown to be well-tolerated and to cause relatively few hypoglycemic events, despite exerting a potent glucose-lowering effect by promoting endogenous insulin secretion, besides also having extrapancreatic effects. Meanwhile, the use of DPP-4 inhibitors has been reported to be associated with the...